TrialJournal for immunotherapy of cancer2020

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.

Xiaofeng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.